$21.8 billion drug maker, Eli Lilly and Co., said it plans to create four new senior-level ethics and compliance positions to further support the centralized global compliance and enterprise risk management function, the company said in a filing. The establishment of the new positions are part of a deal to settle two shareholder lawsuits over the improper marketing of numerous of its drugs.
When they are hired, all four of the new executives will report to Anne Nobles, Lilly’s chief ethics and compliance officer. The four new positions are:
